Wild F
Wissenschaftliches Institut der PKV (WIP), Gustav-Heinemann-Ufer 74c, 50968, Köln, Deutschland.
Nervenarzt. 2013 Feb;84(2):202-8. doi: 10.1007/s00115-012-3683-6.
For persons covered by statutory health insurance (SHI) an increase in the number of defined daily doses (DDD) for pharmaceuticals to treat multiple sclerosis (MS) is known but so far there has been no comparable survey for private health insurance (PHI). Moreover, there are gaps in knowledge of the reasons for the increase and concerning the number of the MS patients in Germany.
The study is based on pharmaceutical data of the PHI in Germany. The projection takes into account the different prevalence and the different male/female relationship in SHI and PHI in an extrapolation to the total population.
From 2006 to 2010 the number of DDDs of MS pharmaceuticals increased by approximately 91.6 % (SHI 39.9 %) per insured person. The increase in the PHI is mainly based for on an increase in the number of MS patients. The total number of MS patients in Germany was estimated to be approximately 146,000 whereby some 12,700 MS patients (8.7 %) were insured in PHI.
There is a need for research into the reasons for the increase in MS patients. The disproportional increase in the PHI compared to SHI could be a result of the increase of insured persons and an increased inclusion of persons with a higher risk of the disease.
对于法定医疗保险（SHI）覆盖的人群，用于治疗多发性硬化症（MS）的药品限定日剂量（DDD）数量有所增加，这是已知的，但迄今为止，尚未对私人医疗保险（PHI）进行类似的调查。此外，对于德国MS患者数量增加的原因以及MS患者数量方面，存在知识空白。
该研究基于德国私人医疗保险的药品数据。在对总人口进行外推时，该预测考虑了法定医疗保险和私人医疗保险中不同的患病率以及不同的男女比例关系。
2006年至2010年期间，每位被保险人的MS药品DDD数量增加了约91.6%（法定医疗保险为39.9%）。私人医疗保险中的增加主要是由于MS患者数量的增加。据估计，德国MS患者总数约为146,000人，其中约12,700名MS患者（8.7%）参加了私人医疗保险。
有必要对MS患者数量增加的原因进行研究。与法定医疗保险相比，私人医疗保险中不成比例的增加可能是被保险人数量增加以及疾病风险较高人群纳入增加的结果。
